Michelle Mierzwa, MD, on Oropharyngeal Cancer: Early Results on De-escalated Radiotherapy

March 21, 2022 By The ASCO Post Staff

Michelle Mierzwa, MD, of the University of Michigan, discusses early findings from a phase II trial of FDG-PET (fluorodeoxyglucose–positron-emission tomography) de-escalated radiotherapy for patients with p16-positive orophyaryngeal cancer. An interim analysis suggests that for approximately half of patients with stage I or II disease, this type of treatment may decrease toxicity and improve quality of life.

Related Content